Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00191061 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 640
- Enrollment target
NCT00191061: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT00191061 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 640 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (24% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00191061, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 640 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the tolerability and efficacy of different doses of duloxetine in patients with major depressive disorder.
Interventions
- DRUG duloxetine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 640 participants |
| Start Date | 2004-10 |
| Est. Completion | 2006-01 |
| Phase | Phase 4 |
What the finished NCT00191061 record still lists
NCT00191061 is an interventional study that assigns participants to a tested intervention. The registered 640 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (24% higher).
The record links to 0 conditions, and to 1 intervention - of which duloxetine hydrochloride is the first listed.
NCT00191061 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00191061 about?
NCT00191061 is a clinical study titled "A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder". The purpose of this study is to compare the tolerability and efficacy of different doses of duloxetine in patients with major depressive disorder.
What is the current status of trial NCT00191061?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 640 participants. The study started on 2004-10. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00191061?
The interventions under investigation include: duloxetine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00191061?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00191061's enrollment target sits among peer trials
640 127th of 2000 higher than 1,874 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04339699 · 640 participants · NA
NobleStitch EL STITCH Trial is a PFO Comparative Trial
- NCT04979338 · 640 participants · Phase 3
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries
- NCT05156398 · 640 participants · Phase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- NCT05930483 · 640 participants · NA
Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia